心血管康复医学杂志
心血管康複醫學雜誌
심혈관강복의학잡지
JOURNAL OF CARDIOVASCULAR REHABILITATION MEDICINE
2014年
3期
306-308
,共3页
前列腺增生%高血压%非那雄胺
前列腺增生%高血壓%非那雄胺
전렬선증생%고혈압%비나웅알
Prostatic hyperplasia%Hypertension%Finasteride
目的:分析应用非那雄胺对老年单纯收缩期高血压(ISH)合并良性前列腺增生(BPH)患者的疗效及安全性。方法:选择84例2011年6月至2013年5月我院的ISH合并BPH老年患者,依据给药方案不同分为:非那雄胺组(44例);常规治疗组(40例,行常规治疗不使用非那雄胺)。疗程均为半年,比较两组国际前列腺症状评分(IPSS)、生活质量评分(QOL),前列腺特异性抗原(PSA)、急性尿潴留发生率、最大尿流率(Qmax)、膀胱残余尿量(PRV)、前列腺体积(PV)以及不良反应发生率。结果:与常规治疗组相比,非那雄胺组的 IPSS 评分[(13.2±2.4)分比(9.4±1.1)分]、PRV [(21.4±4.6)ml比(9.0±2.3)ml]、PV [(36.8±3.8)ml比(29.5±3.0)ml]、PSA [(2.45±0.74)μg/L比(1.26±0.48)μg/L]及急性尿潴留发生率(17.50%比9.09%)显著降低(P<0.05或<0.01),而 Qmax [(10.2±2.4)ml比(13.7±3.8)ml]及 QOL评分[(3.1±1.0)分比(4.7±1.5)分]则显著升高(P<0.05)。两组各项不良反应发生率无统计学差异(P 均>0.05)。结论:单纯收缩期高血压合并良性前列腺增生老年患者应用非那雄胺的疗效显著,且不良反应未显著增加。
目的:分析應用非那雄胺對老年單純收縮期高血壓(ISH)閤併良性前列腺增生(BPH)患者的療效及安全性。方法:選擇84例2011年6月至2013年5月我院的ISH閤併BPH老年患者,依據給藥方案不同分為:非那雄胺組(44例);常規治療組(40例,行常規治療不使用非那雄胺)。療程均為半年,比較兩組國際前列腺癥狀評分(IPSS)、生活質量評分(QOL),前列腺特異性抗原(PSA)、急性尿潴留髮生率、最大尿流率(Qmax)、膀胱殘餘尿量(PRV)、前列腺體積(PV)以及不良反應髮生率。結果:與常規治療組相比,非那雄胺組的 IPSS 評分[(13.2±2.4)分比(9.4±1.1)分]、PRV [(21.4±4.6)ml比(9.0±2.3)ml]、PV [(36.8±3.8)ml比(29.5±3.0)ml]、PSA [(2.45±0.74)μg/L比(1.26±0.48)μg/L]及急性尿潴留髮生率(17.50%比9.09%)顯著降低(P<0.05或<0.01),而 Qmax [(10.2±2.4)ml比(13.7±3.8)ml]及 QOL評分[(3.1±1.0)分比(4.7±1.5)分]則顯著升高(P<0.05)。兩組各項不良反應髮生率無統計學差異(P 均>0.05)。結論:單純收縮期高血壓閤併良性前列腺增生老年患者應用非那雄胺的療效顯著,且不良反應未顯著增加。
목적:분석응용비나웅알대노년단순수축기고혈압(ISH)합병량성전렬선증생(BPH)환자적료효급안전성。방법:선택84례2011년6월지2013년5월아원적ISH합병BPH노년환자,의거급약방안불동분위:비나웅알조(44례);상규치료조(40례,행상규치료불사용비나웅알)。료정균위반년,비교량조국제전렬선증상평분(IPSS)、생활질량평분(QOL),전렬선특이성항원(PSA)、급성뇨저류발생솔、최대뇨류솔(Qmax)、방광잔여뇨량(PRV)、전렬선체적(PV)이급불량반응발생솔。결과:여상규치료조상비,비나웅알조적 IPSS 평분[(13.2±2.4)분비(9.4±1.1)분]、PRV [(21.4±4.6)ml비(9.0±2.3)ml]、PV [(36.8±3.8)ml비(29.5±3.0)ml]、PSA [(2.45±0.74)μg/L비(1.26±0.48)μg/L]급급성뇨저류발생솔(17.50%비9.09%)현저강저(P<0.05혹<0.01),이 Qmax [(10.2±2.4)ml비(13.7±3.8)ml]급 QOL평분[(3.1±1.0)분비(4.7±1.5)분]칙현저승고(P<0.05)。량조각항불량반응발생솔무통계학차이(P 균>0.05)。결론:단순수축기고혈압합병량성전렬선증생노년환자응용비나웅알적료효현저,차불량반응미현저증가。
Objective:To analyze the therapeutic effect and safety of finasteride on aged patients with isolated systolic hypertension (ISH)complicated benign prostatic hyperplasia (BPH).Methods:A total of 84 aged ISH + BPH pa-tients admitted from Jun 2011 to May 2013 were selected.According to medication plan,they were divided into fin-asteride group (n=44)and routine treatment group (n=40,only received routine treatment because they cannot use finasteride).Course of treatment was all six months.International prostate symptom score (IPSS),quality of life (QOL) questionnaire score,prostate-specific antigen (PSA),incidence rate of acute urinary retention,maximum u-rinary flow rate (Qmax),postvoid residual urine (PRV),prostate volume (PV)and incidence rate of adverse reac-tions were compared between two groups.Results:Compared with routine treatment group,there were significant reductions in IPSS [(13.2±2.4)scores vs.(9.4±1.1)scores],PRV [(21.4±4.6)ml vs.(9.0±2.3)ml],PV [(36.8±3.8)ml vs.(29.5±3.0)ml],PSA [(2.45±0.74)μg/L vs.(1.26±0.48)μg/L]and incidence rate of acute urinary retention (17.50% vs.9.09%),P<0.05 or <0.01,and significant increase in Qmax [(10.2±2.4) ml vs.(13.7±3.8)ml]and QOL score [(3.1±1.0)scores vs.(4.7±1.5)scores]in finasteride group (P<0.05). There were no significant difference in incidence rates of adverse reactions between two groups,P>0.05 all.Con-clusion:Therapeutic effect of finasteride is significant and adverse reactions don’ t increase significantly in aged pa-tients with isolated systolic hypertension complicated benign prostatic hyperplasia.